Lenalidomide and Chronic Lymphocytic Leukemia

Lenalidomide is an oral immunomodulatory drug used in multiple myeloma and myelodysplastic syndrome and most recently it has shown to be effective in the treatment of various lymphoproliferative disorders such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. The mechanism of action of...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2013-01, Vol.2013 (2013), p.1-9
Main Authors: González, Segundo, Villa-Alvarez, Monica, Huergo-Zapico, Leticia, Acebes-Huerta, Andrea, Payer, Angel R., González-Rodríguez, Ana Pilar, Gonzalez-García, Esther
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal, Murine-Derived - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Clinical Trials as Topic
Drug therapy
Humans
Immune system
Immunologic Factors - administration & dosage
Immunologic Factors - adverse effects
Immunologic Factors - therapeutic use
Immunomodulation
Lenalidomide
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell - immunology
Leukemia, Lymphocytic, Chronic, B-Cell - therapy
Lymphocytes
Review
Rituximab
Thalidomide - administration & dosage
Thalidomide - adverse effects
Thalidomide - analogs & derivatives
Thalidomide - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lenalidomide is an oral immunomodulatory drug used in multiple myeloma and myelodysplastic syndrome and most recently it has shown to be effective in the treatment of various lymphoproliferative disorders such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. The mechanism of action of lenalidomide varies depending on the pathology, and in the case of CLL, it appears to primarily act by restoring the damaged mechanisms of tumour immunosurveillance. This review discusses the potential mechanism of action and efficacy of lenalidomide, alone or in combination, in treatment of CLL and its toxic effects such as tumor lysis syndrome (TLS) and tumor flare reaction (TFR), that make its management different from other hematologic malignancies.
ISSN:2314-6133
2314-6141
DOI:10.1155/2013/932010